Table 1.

Patients and TMAs included and excluded in each data group

Cohort	BCCA				MA31
Biomarker	PD-L1		PD-1		PD-L1
Total patients	n	%	n	%	n	%
Total	4944	100.0%	4944	100.0%	652	100.0%
Excluded from analysis	1568	31.7%	1449	29.3%	377	57.8%
Included in analysis	3376	68.3%	3495	70.7%	275	42.2%
Patients excluded from analysis	n	%	n	%	n	%
Total	1568	100.0%	1449	100.0%	377	100.0%
No TMAs	168	10.7%	0	0.0%	229	60.7%
No tissue	969	61.8%	1189	82.1%	118	31.3%
No tumor	176	11.2%	188	13.0%	25	6.6%
Deficient staining	224	14.3%	61	4.2%	5	1.3%
Out of focus	31	2.0%	11	0.8%	0	0.0%
Patients included in analysis	n	%	n	%	n	%
Total	3376	100.0%	3495	100.0%	275	100.0%
Negative	2819	83.5%	3388	96.9%	252	91.6%
Positive	557	16.5%	107	3.1%	23	8.4%
Training set	2516	74.5%	2618	74.9%	0	0.0%
Test set	860	25.5%	877	25.1%	275	100.0%
H&E TMAs included in analysis	n	%	n	%	n	%
Total	10,128	100.0%	10,485	100.0%	515	100.0%
Negative	8457	83.5%	10164	96.9%	482	93.6%
Positive	1671	16.5%	321	3.1%	33	6.4%
Training set	7548	74.5%	7854	74.9%	0	0.0%
Test set	2580	25.5%	2631	25.1%	515	100.0%
IHC TMAs included in analysis	n	%	n	%	n	%
Total	3376	100.0%	3495	100.0%	515	100.0%
Negative	2819	83.5%	3388	96.9%	482	93.6%
Positive	557	16.5%	107	3.1%	33	6.4%
Training set	2516	74.5%	2618	74.9%	0	0.0%
Test set	860	25.5%	877	25.1%	515	100.0%